Business ❯ Healthcare ❯ Pharmaceuticals

Acquisitions

Biogen Novo Nordisk Johnson & Johnson US WorldMeds AstraZeneca Melinta Therapeutics Sanofi Metsera Pfizer Merck and Cidara Acquisition Alkermes Novartis-Avidity Acquisition Sanofi-Dren Bio Agreement Merck Eris Lifesciences Organon-Dermavant Merck KGaA Cipla Eli Lilly and Verve Therapeutics GSK Acquisition of RAPT Therapeutics Sanofi and Dynavax Ophthalmology Eli Lilly Neurocrine Biosciences

Neurocrine to Acquire Soleno for $2.9 Billion in All-Cash Tender

The purchase secures the lone FDA-approved therapy for Prader-Willi hunger to drive a rare-disease push.

Lilly to Acquire Centessa for $6.3 Billion to Add Orexin Sleep Drugs

Pfizer Tops Q4 Estimates but Posts Loss on $4.4 Billion Charge, Reaffirms 2026 Outlook

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

CorMedix Shares Jump After Q3 Beat as Company Lifts 2025 Outlook

Alkermes to Buy Avadel in Up to $2.1 Billion Deal With CVR Tied to Lumryz Expansion

Novo Nordisk to Acquire Akero for Up to $5.2 Billion to Expand in MASH

DoorDash Signs Multi-Year Deal to Use Serve Robotics’ Sidewalk Bots for Deliveries

Adaptimmune Sells Tecelra and Late-Stage Cell Therapies to U.S. WorldMeds for $55M

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline